Angiogenesis inhibitors in gastric and gastroesophageal junction cancer

Roviello, Giandomenico; Petrioli, Roberto; Marano, Luigi; Połom, Karol; Marrelli, Daniele; Perrella, Armando; Roviello, Franco

doi:10.1007/s10120-015-0537-5

Cited by 48 publications

(37 citation statements)

References 74 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may be also used with predictive purposes when assessing the efficacy of newer drugs. Notably, it was already shown that HER-2 amplification is mostly found in intestinal-type and proximal cancers (89), while FGFR2 amplification is typical of diffuse tumors (90), and even antiangiogenic drugs may be more effective in intestinal-type GC (91).…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis

Petrelli¹,

Berenato²,

Turati³

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis

Petrelli¹,

Berenato²,

Turati³

et al. 2017

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

“…VEGFR-2 activation can be inhibited using a number of pharmacodynamic approaches, including receptor blockade (ramucirumab), ligand capture (bevacizumab, also known as avastin), and small-molecule inhibition (sorafenib, sunitinib, apatinib, and cediranib) [ 28 ]. The patient described in this report experienced disease progression following gemcitabine-docetaxel chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Advanced alveolar soft part sarcoma responds to apatinib

et al. 2017

View full text Add to dashboard Cite

Alveolar soft part sarcoma (ASPS) is a rare, hypervascular soft tissue sarcoma with a low chemotherapy response rate. Here, we report an ASPS case with multiple lung metastases on initial presentation. The primary tumor, a hypervascular soft tissue mass 4.1×3.2×2.0 cm, located in the right thigh, was resected prior to chemotherapy. The patient suffered disease progression after two cycles of gemcitabine-docetaxel treatment. Immunohistochemical examination of the tumor tissue revealed strong positive staining for vascular endothelial growth factor (VEGF) and VEGF receptor-2 (VEGFR-2). The patient was subsequently treated with apatinib (500 mg/day), a specific VEGFR-2 inhibitor. Treatment was well tolerated, and the patient exhibited a partial response, with the lung metastases reduced in size and number after one month of therapy. To date, 12-month progression-free survival has been achieved. Apatinib may provide an additional treatment option for metastatic ASPS, particularly in cases resistant to other chemotherapeutic options. Furtherstudies with more cases with longer follow-up times will be necessary to determine the clinical efficacy of apatinib for treatment of ASPS.

show abstract

“…The Cancer Genome Atlas Research Network (TCGA) has demonstrated a subset of GC with a recurrent amplification of the VEGF-A gene and with an elevated expression of angiogenesis-related pathways [31-34]. In addition, several trials showed that the expression of VEGFR2 is related to a poor prognosis in patients with metastatic GC [35]. Given the molecular evidence that the VEGF pathway is upregulated in only a subset of GC cancers, it may be beneficial to pursue predictive biomarkers for anti-VEGF pathway therapies in this cancer.…”

Section: Expert Commentarymentioning

confidence: 99%